Organigram GlobalSTU:0OG +7.60%64 Gross Margin % is 27.44% as of Mar. 2026, which is 15% below its 10-year median of 32.27. GuruFocus rates STU:0OG with a GF Score™ of 64/100 and a GF Value™ of €1.47 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 935 Drug Manufacturers companies, Organigram Global ranks worse than 72.73% on this metric.
The historical rank and industry rank for Organigram Global's Gross Margin % or its related term are showing as below:
STU:0OG'
s Gross Margin % Range Over the Past 10 Years
Min: -65.08 Med: 32.27 Max: 415.42
Current: 35.64
During the past 13 years, the highestGross Margin % of Organigram Global was 415.42%. The lowest was -65.08%. And the median was 32.27%.
STU:0OG's Gross Margin % is ranked worse than 72.73% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs STU:0OG: 35.64
Organigram Global had a gross margin of 27.44% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Organigram Global was 0.00% per year.
Organigram Global (STU:0OG) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Organigram Global had a gross margin of 27.44% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Organigram Global Gross Margin % Related Terms
Organigram Global Gross Margin % Historical Data
* Premium members only.
The historical data trend for Organigram Global's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organigram Global Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organigram Global's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Organigram Global's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Organigram Global (STU:0OG) has a Gross Margin % of 27.44% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Organigram Global and its competitors. This is 15% below median its historical median of 32.27. According to the industry distribution chart, Organigram Global ranks #680 out of 935 companies in the Drug Manufacturers industry, placing it in the top 72.7%.
Is Organigram Global's Gross Margin % too high?
Organigram Global's current Gross Margin % of 27.44% is 15% below median its 10-year median of 32.27. The Drug Manufacturers industry median Gross Margin % is 48.54. Organigram Global's value of 27.44% is 43.5% below this industry median. Based on the distribution chart, Organigram Global ranks #680 out of 935 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Organigram Global has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Organigram Global ranks #680 out of 935 companies for Gross Margin %. This places Organigram Global in the lower half of its industry. The industry median Gross Margin % is 48.54. Organigram Global's value of 27.44% is 43.5% below this benchmark. While the company's 10-year median is 32.27 vs. the industry median of 48.54, Organigram Global has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organigram Global's current Gross Margin % of 27.44% is 43.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Organigram Global and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organigram Global's current Gross Margin % is 27.44%, which is 15% below median its own 10-year median of 32.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.47, compared to a current price of €0.88 — trading 40.3% below its estimated fair value. The current Gross Margin % is 27.44%, which is 15% below median its 10-year median of 32.27 and 43.5% below the Drug Manufacturers industry median of 48.54. Organigram Global's overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current Gross Margin % is 27.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organigram Global (STU:0OG) Overvalued in 2026?
Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued.
The current stock price of €0.88 is trading 40.3% below its estimated GF Value™ of €1.47.
GuruFocus considers Organigram Global to be Possible Value Trap.
Key valuation signals for STU:0OG:
Gross Margin %: 27.44% (15% below median its 10-year median of 32.27)
GF Value™: €1.47 vs. price of €0.88 (40.3% below fair value)
Industry Position: 43.5% below the Drug Manufacturers median (#680 of 935)
No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
64GF Score
Get the complete analysis for STU:0OG
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0OG has been successfully added to your 
